Three prescription GLP-1 pills are actually on the U.S. market as of September 2026, and all three are priced in almost exactly the same band. That is the useful thing to know before you start shopping: which pill you end up on matters far less to your monthly bill than whether you buy it through the manufacturer’s own pharmacy or through a retail counter.
Everything below was pulled on September 4, 2026 from Eli Lilly’s LillyDirect pages, Novo Nordisk’s NovoCare Pharmacy pages, the federal TrumpRx site, and the CMS National Average Drug Acquisition Cost (NADAC) file. This is the category comparison. For dose-by-dose detail on any one brand, follow the link to that brand’s own guide.
What Do GLP-1 Pills Cost Without Insurance?
Self-pay prices are what a cash patient pays through the manufacturer’s direct pharmacy, outside of insurance. NADAC is what a retail pharmacy typically pays to buy the bottle, which is the closest public proxy for a real counter price.
| Oral GLP-1 | Low | Average | High |
|---|---|---|---|
| Foundayo (orforglipron), LillyDirect self-pay | $149/mo (0.8 mg, 2.5 mg) | $199/mo (5.5 mg) | $299/mo (9 mg, 14.5 mg, 17.2 mg) |
| Wegovy tablets (oral semaglutide), NovoCare self-pay | $149/mo (1.5 mg) | $199/mo (4 mg) | $299/mo (9 mg, 25 mg) |
| Ozempic pill (oral semaglutide, diabetes), NovoCare self-pay | $149/mo | $199/mo | $299/mo |
| Any of the three, commercial insurance plus savings card | $25/mo | $25/mo | savings capped by the card terms |
| Pharmacy acquisition cost (NADAC, 30 tablets) | $619.69 (Foundayo 5.5 mg) | about $995 (oral semaglutide 30 tablets) | $1,305.43 (Wegovy 1.5 mg tablets) |
| Manufacturer list price (WAC) | $649.00/mo (Foundayo) | - | $1,349.02/mo (Wegovy tablets) |
The NADAC figures carry an effective date of August 19, 2026, the most recent vintage in the CMS file as of this writing. Self-pay and list prices were checked September 4, 2026.
Foundayo’s $149 price on the 2.5 mg dose and $199 on 5.5 mg are temporary reductions that run through December 31, 2026, after which those doses return to $199 and $299, per the disclaimer Lilly publishes on both LillyDirect and TrumpRx. The 14.5 mg and 17.2 mg doses hold at $299 only if you refill within 45 days; miss that window and the price is $349.
The three pills, and what each one is for
Foundayo (orforglipron) is Eli Lilly’s oral GLP-1, and it is not semaglutide. It is a different molecule with a different list price: $649 a month, roughly half of Novo Nordisk’s tablets, and it carries the lowest acquisition cost of any oral GLP-1 in the CMS file. It is approved for weight management. Full dose ladder on our Foundayo cost guide, and the molecule-level detail on orforglipron.
Wegovy tablets are oral semaglutide at 1.5, 4, 9, and 25 mg, approved for weight management and cardiovascular risk reduction. This is the pill most people mean when they search for a weight-loss GLP-1 pill. See oral Wegovy cost for the full dose table.
The Ozempic pill is oral semaglutide at 1.5, 4, and 9 mg, approved for type 2 diabetes, and it is the newer sibling of Rybelsus, the 3 / 7 / 14 mg oral semaglutide tablet. The older Rybelsus tablet has no equivalent self-pay program price, and the CMS acquisition-cost file puts it at about $33.16 per tablet as of August 19, 2026, roughly $995 for a 30-tablet month before any pharmacy markup. That is the practical argument for asking your prescriber which oral semaglutide product you are actually being written for.
What Drives the Price
The channel, not the pharmacy. The single biggest variable is whether the prescription goes to LillyDirect or NovoCare Pharmacy as a self-pay claim, or to a retail counter as a normal cash claim. That one choice is the difference between $149 and roughly four figures on the same bottle.
Your dose. Every one of these programs is a ladder, not a flat price. Budget for the maintenance dose you expect to land on, not the starter dose in the headline. On all three pills that means $299 a month, not $149.
Whether you refill on time. Lilly ties its top-dose pricing to a 45-day refill window on both Foundayo and Zepbound. A late refill on Foundayo 14.5 mg or 17.2 mg moves you from $299 to $349.
Promotional windows. Two of Foundayo’s six dose prices are temporarily reduced through December 31, 2026. Novo’s $199 introductory injection pricing is also time-boxed. Anything described as an introductory or temporary price should be treated as a price that will change.
Whether you have commercial insurance at all. With a commercial plan that covers the drug, the savings cards on all three pills land you near $25 a month. Government beneficiaries, including anyone on Medicare or Medicaid, are excluded from those cards.
Pills vs. Injections: Is the Pill Actually Cheaper?
At maintenance doses, yes, and by a meaningful margin. At the very bottom of the ladder, not always.
| Product | Self-pay price | Form |
|---|---|---|
| Foundayo, Wegovy tablets, Ozempic pill | $149 to $299/mo | pill |
| Wegovy injection | $199/mo intro (2 fills, through Dec 31, 2026), then $349/mo, $399 for Wegovy HD 7.2 mg | pen |
| Ozempic injection | $199/mo intro (2 fills, through Dec 31, 2026), then $349/mo, $499 for 2 mg | pen |
| Zepbound (KwikPen or vial) | $299/mo (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg on-time refill), $499 to $699 if you miss a fill | pen or vial |
The pills cap out at $299. The injections do not. Once you are at a maintenance dose, a pill is $50 to $400 a month cheaper than an injectable bought the same way, which is $600 to $4,800 a year. Our Zepbound vs. Wegovy cost comparison covers the two injectables head to head, and tirzepatide cost covers the molecule.
The catch is that they are not interchangeable drugs. Foundayo and Wegovy tablets are approved for weight management; the Ozempic pill is approved for type 2 diabetes; Zepbound and Mounjaro are tirzepatide, a different molecule entirely. Price should break a tie between clinically reasonable options, not pick the option.
What Is Not a Real GLP-1 Pill
Search for GLP-1 pills and you will be marketed two things that are not FDA-approved oral GLP-1 drugs. Both are worth naming plainly.
Over-the-counter “GLP-1 support” supplements. No dietary supplement sold over the counter is an FDA-approved GLP-1 medicine. Every approved GLP-1 in the United States, tablet or injection, requires a prescription from a licensed prescriber, a point Novo Nordisk states flatly in its own patient FAQ. Capsules marketed as GLP-1 boosters, GLP-1 activators, or natural GLP-1 are sold under the dietary supplement framework, which means no agency reviewed them for weight-loss effectiveness before they went on sale. They are not cheaper versions of the drugs on this page. They are a different category of product.
Compounded oral semaglutide sold by telehealth sellers. FDA’s standing statement on unapproved GLP-1 drugs, current as of September 1, 2026, is that compounded versions are not FDA approved and are not reviewed for safety, effectiveness, or quality before marketing. The agency specifically flags fraudulent compounded semaglutide carrying the names of pharmacies that did not make it, salt forms such as semaglutide sodium and semaglutide acetate that are not the approved active ingredient, and adverse events including hospitalizations tied to dosing errors. As of May 31, 2026, FDA had logged 990 adverse event reports for compounded semaglutide.
FDA’s own consumer red-flag list is worth memorizing before you buy from any telehealth site: claims that a compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, no screening or prescription by a licensed doctor, and packaging or labels that look wrong.
Cash Price vs. Insurance
For these three pills, the cash price is often the better deal, which is unusual in American healthcare. Novo Nordisk and Eli Lilly both price their direct self-pay channels below what an uncovered insurance claim would cost you at retail, and both let you use FSA or HSA funds.
The trade-off is real, though. NovoCare states it directly: a self-pay prescription is processed outside your insurance, does not count toward your deductible, and cannot be applied to your out-of-pocket maximum. If you have a plan that genuinely covers the drug, run the savings card first and compare. If your plan denies it or excludes weight-loss drugs, self-pay is the whole game.
Medicare and Medicaid beneficiaries are excluded from the commercial savings cards entirely but can still use the self-pay channel by paying outside their plan. If you are on Medicare, read our guide to Medicare GLP-1 coverage and cost first, because a separate federal program may put you at $50 a month.
How to Pay Less
1. Start at the manufacturer, not the pharmacy. Ask your prescriber to send the prescription to LillyDirect or NovoCare Pharmacy as a self-pay prescription. This is the single highest-value move on this page and it is worth several hundred dollars a month. Our cheapest GLP-1 guide walks through every current program side by side.
2. Price the dose you will actually be on. Ask your prescriber where the ladder is likely to end for you and price that dose, not the starter. A plan built on $149 that ends at $299 is a plan that breaks.
3. Set a refill reminder for day 40. On Lilly’s top doses, refilling within 45 days is worth $50 a month on Foundayo and up to $250 a month on Zepbound. See cheapest way to get Zepbound for how that program works.
4. Run the savings card if you have commercial coverage. All three pills have a card that can put an eligible commercially insured patient near $25 a month. It is worthless if your plan excludes the drug, and unavailable if you are on any government plan.
5. Compare card prices before filling at retail. If you are stuck at a retail counter, discount cards are the only lever left, and the spread between chains on the same bottle can be hundreds of dollars. Our GoodRx vs. SingleCare comparison covers how to check both, and quoted card prices shift by pharmacy and by day, so check on the day you fill.
6. Do not chase a price below the approved market. Anything advertised well under $149 a month for an oral GLP-1 is not one of the three drugs on this page. Check the current fair range on our fair price tool before you believe an offer.
The Bottom Line
As of September 2026, every real oral GLP-1 in the United States sits between $149 and $299 a month if you buy it directly from the manufacturer as a self-pay patient, and between roughly $620 and $1,349 a month if you do not. The pills are now cheaper than the pens at maintenance doses, the temporary prices in that band expire December 31, 2026, and nothing sold over the counter belongs in the comparison at all. If you want the broader picture including the injectables, start with GLP-1 cost without insurance.